- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04968184
Eficácia e segurança do KBP-5074 em hipertensão não controlada e DRC moderada ou grave (Clarion-CKD)
Um estudo multicêntrico randomizado, duplo-cego e controlado por placebo de Fase 3 para avaliar a eficácia e a segurança do antagonista do receptor de mineralocorticoide KBP-5074 em indivíduos com hipertensão não controlada e DRC moderada ou grave (estágio 3b/4)
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula [eGFR {EPI}] ≥15 to ≤44 mL/min/1.73 m^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and <180 mm Hg and taking 2 or more antihypertensive medications.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Participants in this study will be recruited, screened, and enrolled at approximately 140 study sites globally.
The study will consist of the following periods:
- Pretreatment Phase: This will include prescreening assessment and screening period of up to 4 weeks and 2-week Open-label placebo Run-In period.
- A 24-week Double-blind Treatment Period (Randomization to Week 24) will include: An initial 12-week (Randomization to Week 12) and second 12-week (Week 12 to Week 24) treatment period and a second 12-week treatment period (Week 12 to Week 24), during both the periods study drug will be titrated.
- A 24-week Open-label Treatment Period (Week 24 to Week 48) during which eligible participants will receive Open-label KBP-5074.
- A 4-week Randomized Double-blind Withdrawal Period (Week 48 to Week 52) during which eligible participants will be randomized to continue their current KBP-5074 dose at the end of Open-label treatment or receive matching placebo for 4 weeks.
- A 4-week post-treatment Follow-Up Period (Week 52 to Week 56).
During, 24-week Double-blind Treatment Period, 24-week Open-label Treatment Period, and at 4-week Randomized Double-blind Withdrawal Period, the background antihypertensive medications change may or may not be allowed.
At Double-blind Treatment Period, eligible participants will be randomly assigned in a 1:1 ratio to KBP-5074 0.25 mg or matching placebo once daily (QD).
At the Randomized Double-blind Withdrawal Period, participants who meet the randomized withdrawal criteria will be randomly assigned in a 1:1 ratio to continue their current KBP-5074 dose at the end of the Open-label Treatment Period or matching placebo QD.
The study design included a pre-planned futility determination by an Independent Data Monitoring Committee (IDMC).
The trial was originally sponsored by KBP Biosciences PTE Ltd, but sponsorship was transferred to Novo Nordisk after the trial was terminated following the futility determination by IDMC.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, 12203
- Charité - Universitätsmedizin Berlin
-
Berlin, Alemanha, 10117
- Charité- Universitätsmedizin Berlin
-
Hanover, Alemanha, 30625
- Medizinische Hochschule Hannover
-
Jena, Alemanha, 07747
- Universitätsklinikum Jena
-
-
Baden-Wurttemberg
-
Villingen-Schwenningen, Baden-Wurttemberg, Alemanha, 78052
- Nephrologisches Zentrum Villingen-Schwenningen
-
-
North Rhine-Westphalia
-
Dortmund, North Rhine-Westphalia, Alemanha, 44137
- Diabeteszentrum DO
-
Düsseldorf, North Rhine-Westphalia, Alemanha, 23538
- DaVita Clinical Research Germany GmbH
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Alemanha, 55131
- Universitätsklinikum Mainz
-
-
-
-
New South Wales
-
Gosford, New South Wales, Austrália, 2250
- Renal Research
-
-
South Australia
-
Adelaide, South Australia, Austrália, 5000
- Royal Adelaide Hospital
-
-
Victoria
-
Heidelberg, Victoria, Austrália, 3084
- Austin Hospital
-
-
-
-
-
Gabrovo, Bulgária, 5300
- Mhat Dr.Tota Venkova
-
Montana, Bulgária, 3400
- Medical Center Hera EOOD
-
Plovdiv, Bulgária, 4002
- UMHAT Kaspela
-
Rousse, Bulgária, 7012
- Medical Center "Teodora"
-
Sofia, Bulgária, 1510
- Medical Center Hera EOOD
-
Sofia, Bulgária, 1113
- DCC 22 - Sofia
-
Sofia, Bulgária, 1784
- Medical Center ''Synexus Sofia'' EOOD
-
Stara Zagora, Bulgária, 6000
- University Hospital of Active Treatment Prof. Stoyan Kirkovich
-
Varna, Bulgária, 9002
- MHAT"Sv.Anna-Varna"AD
-
-
Sofia-Grad
-
Sofia, Sofia-Grad, Bulgária, 1233
- 5 th MHAT
-
Sofia, Sofia-Grad, Bulgária, 1407
- Medical Center Excelsior
-
Sofia, Sofia-Grad, Bulgária, 1431
- UMHAT St. Ekaterina
-
Sofia, Sofia-Grad, Bulgária, 1612
- Comac Medical Ltd
-
-
-
-
Kanton Sarajevo
-
Sarajevo, Kanton Sarajevo, Bósnia e Herzegovina, 71000
- Clinical Center University of Sarajevo
-
-
Republika Srpska
-
Banja Luka, Republika Srpska, Bósnia e Herzegovina, 78000
- Univerzitetski klinicki centar Republike Srpske - Internal Medicine, Nephrology
-
Foca, Republika Srpska, Bósnia e Herzegovina, 73300
- The University Hospital Foca
-
Gradiska, Republika Srpska, Bósnia e Herzegovina, 78400
- General Hospital Gradiska
-
Trebinje, Republika Srpska, Bósnia e Herzegovina, 89101
- General hospital Trebinje - Gastroenterology
-
-
Zeničko-dobojski Kanton
-
Tešanj, Zeničko-dobojski Kanton, Bósnia e Herzegovina, 72460
- General Hospital Tesanj
-
-
-
-
Ontario
-
Toronto, Ontario, Canadá, M4C 5T2
- Dr. Stephen S. Chow Medicine Professional Corporation
-
Waterloo, Ontario, Canadá, N2T 0C1
- Clinical Research Solutions Incorporated
-
-
-
-
-
Chongqing, China, 400038
- The Southwest Hospital of AMU
-
Shanghai, China, 200233
- Shanghai Sixth People's Hospital
-
Tianjin, China, 300052
- Tianjin Medical University General Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Peking University First Hospital
-
Beijing, Beijing Municipality, China, 100029
- China-Japan Friendship Hospital
-
Beijing, Beijing Municipality, China, 100730
- Beijing Hospital
-
Beijing, Beijing Municipality, China, 100020
- Beijing Chao-Yang Hospital, Capital Medical University
-
Beijing, Beijing Municipality, China, 100029
- Beijing An Zhen Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, China, 350005
- The First Affiliated Hospital of Fujian Medical University
-
Xiamen, Fujian, China, 361003
- The First Affiliated Hospital of Xiamen University
-
Xiamen, Fujian, China, 361004
- Zhongshan Hospital Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Guangdong Provincial People's Hospital
-
Guangzhou, Guangdong, China, 510180
- Guangzhou First People's Hospital - Nephrology
-
Guangzhou, Guangdong, China, 510655
- The Third Affiliated Hospital, Sun Yat-sen University
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- The People's Hospital of Guangxi Zhuang Autonomous Region- Nephrology
-
-
Guizhou
-
Guiyang, Guizhou, China, 550004
- The Affliated Hospital of Guizhou Medical University
-
-
Hebei
-
Shijiazhuang, Hebei, China, 50004
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou University (East Compus)
-
-
Hubei
-
Wuhan, Hubei, China
- The Central Hospital of Wuhan
-
-
Hunan
-
Changsha, Hunan, China, 410011
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, China, 410013
- The Third Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital/ The First Affiliated Hospital with Nanjing Medical University
-
Wuxi, Jiangsu, China, 214023
- Wuxi People's Hospital
-
-
Nei Mongol (mn)
-
Baotou, Nei Mongol (mn), China, 014010
- The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750004
- General Hospital of Ningxia Medical University
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Shandong
-
Jinan, Shandong, China
- Shandong Provincial Hospital
-
Yantai, Shandong, China, 264000
- Yantai Yuhuangding Hospital(Base Cpmpus)
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200000
- Shanghai General Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610072
- Sichuan Academy of Medical Sciences
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, China
- Zhejiang Provincial People's Hospital
-
Hangzhou, Zhejiang, China
- Zhejiang Hospital
-
Jinhua, Zhejiang, China, 321000
- Jinhua Central Hospital
-
Wenzhou, Zhejiang, China, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Seoul, Coréia do Sul, 03080
- Seoul National University Hospital - Nephrology
-
-
Daejeon Gwang'yeogsi [Taejon-Kwangyokshi]
-
Daejeon, Daejeon Gwang'yeogsi [Taejon-Kwangyokshi], Coréia do Sul, 35015
- Chungnam National University Hospital - Nephrology
-
-
Gyeonggido [Kyonggi-do]
-
Goyang-si, Gyeonggido [Kyonggi-do], Coréia do Sul, 10444
- National Health Insurance Service Ilsan Hospital - Nephrology
-
-
Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Coréia do Sul, 6273
- Gangnam Severance Hospital, Yonsei University Health System - Internal Medicine
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Coréia do Sul, 6351
- Samsung Medical Center - Nephrology
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Coréia do Sul, 6591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
-
-
-
-
Split, Croácia, 21000
- University Hospital Center Split
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Croácia, 10000
- University Hospital Centre Zagreb
-
-
Osjecko-baranjska Županija
-
Vinkovci, Osjecko-baranjska Županija, Croácia, 32100
- Opca bolnica Vinkovci
-
-
-
-
-
Barcelona, Espanha, 8023
- Hospital Quironsalud Barcelona
-
Barcelona, Espanha, 08025
- FUNDACION PUIGVERT - Nephrology Department
-
Barcelona, Espanha, 8035
- Hospital de La Santa Creu i Sant Pau
-
Barcelona, Espanha, 8003
- Hospital del Mar
-
Granada, Espanha, 18014
- Hospital Universitario Virgen de las Nieves
-
Lugo, Espanha, 27880
- Hospital público da Mariña
-
Lugo, Espanha, 27880
- Hospital Ribera Polusa
-
Madrid, Espanha, 28040
- Hospital Universitario Fundación Jiménez Díaz
-
Valencia, Espanha, 46026
- Hospital Universitario Y Politécnico La Fe
-
-
Valenciana, Comunidad
-
Valencia, Valenciana, Comunidad, Espanha, 46014
- Consorcio Hospital General Universitario de Valencia
-
-
-
-
Alabama
-
Foley, Alabama, Estados Unidos, 36535
- G & L Research, LLC
-
Huntsville, Alabama, Estados Unidos, 35805
- Apogee Clinical Research, LLC
-
-
Arizona
-
Mesa, Arizona, Estados Unidos, 85210
- Aventiv Research, Inc
-
-
California
-
Beverly Hills, California, Estados Unidos, 90211-2285
- National Heart Institute
-
Granada Hills, California, Estados Unidos, 91344
- Amicis Research Center
-
Granada Hills, California, Estados Unidos, 91324
- Amicis Research Center (Valencia)
-
Lancaster, California, Estados Unidos, 93534
- Amicis Research Center
-
Northridge, California, Estados Unidos, 91325
- Renal Consultants Medical Group - Granada Hills
-
South Gate, California, Estados Unidos, 90280
- United Clinical Research and Innovations
-
Vacaville, California, Estados Unidos, 95687-3557
- Solano Kidney Care
-
Victorville, California, Estados Unidos, 92392
- Desert Cities Dialysis - Amethyst
-
Victorville, California, Estados Unidos, 92395
- Kidney and Hypertension Center
-
-
Connecticut
-
Bloomfield, Connecticut, Estados Unidos, 06002
- Davita Clinical Research-Hartford
-
-
Florida
-
Bradenton, Florida, Estados Unidos, 34208
- Synergy Healthcare
-
Miami, Florida, Estados Unidos, 33155
- Allied Biomedical Research Institute
-
Miami, Florida, Estados Unidos, 33126
- LCC Medical Research
-
Miami, Florida, Estados Unidos, 33032-8225
- Homestead Associates in Research, Inc
-
Miami, Florida, Estados Unidos, 33126-3422
- Total Research Group
-
Miami, Florida, Estados Unidos, 33144
- Oceane 7 Medical&Research Center, Inc.
-
Miami, Florida, Estados Unidos, 33166
- South Florida Research Phase I-Iv, Inc.
-
Miami Lakes, Florida, Estados Unidos, 33014
- Inpatient Research Clinic, LLC
-
Miami Lakes, Florida, Estados Unidos, 33014-5602
- San Marcus Research Clinic, Inc.
-
Naples, Florida, Estados Unidos, 34104
- New Generation Of Medical Research
-
Ocala, Florida, Estados Unidos, 34471
- Sarkis Clinical
-
Orlando, Florida, Estados Unidos, 32808
- Omega Research Orlando, LLC
-
Tampa, Florida, Estados Unidos, 33603
- Genesis Clinical Research
-
Tampa, Florida, Estados Unidos, 33604
- Santos Research Center CORP
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- Fides Clinical Research
-
Augusta, Georgia, Estados Unidos, 30904
- Southeastern Clinical Research Institute, LLC
-
Columbus, Georgia, Estados Unidos, 31904-3650
- Columbus Associates LLC
-
Macon, Georgia, Estados Unidos, 31201-6863
- Central Georgia Kidney Specialists
-
-
Illinois
-
Gurney, Illinois, Estados Unidos, 60031
- Clinical Investigation Specialists, Inc.
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital (MGH) - Renal Associates Clinic
-
-
Minnesota
-
Edina, Minnesota, Estados Unidos, 55435-2129
- InterMed Consultants
-
-
Missouri
-
Hazelwood, Missouri, Estados Unidos, 63042
- Healthcare Research Network
-
Kansas City, Missouri, Estados Unidos, 64111-5964
- Clinical Research Consultants
-
St Louis, Missouri, Estados Unidos, 63136-6111
- St. Louis Heart and Vascular, P.C. (SLHV) - Christian Hospital Office
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89102-1682
- Healor Primary Care /CCT Research
-
Las Vegas, Nevada, Estados Unidos, 89128
- DaVita Clinical Research (Nevada)
-
-
New York
-
Jamaica, New York, Estados Unidos, 11432
- NYC Health + Hospitals / Queens - Diabetes Center of Excellence
-
Ridgewood, New York, Estados Unidos, 11385
- Mattoo & Bhat Medical Associates, PC
-
The Bronx, New York, Estados Unidos, 10461-1900
- Albert Einstein's College of Medicine
-
The Bronx, New York, Estados Unidos, 10461-2710
- Kidney Medical Associates, PLLC
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28801-4104
- Mountain Kidney & Hypertension Associates (MKHA), P.A - Asheville
-
Greenville, North Carolina, Estados Unidos, 27834
- Physicians East, PA
-
Jacksonville, North Carolina, Estados Unidos, 28546
- Eastern Nephrology Associates - Jacksonville
-
New Bern, North Carolina, Estados Unidos, 28562-5200
- Eastern Nephrology Associates - New Bern
-
Raleigh, North Carolina, Estados Unidos, 27609-7511
- North Carolina Nephrology P.A.
-
Winston-Salem, North Carolina, Estados Unidos, 27103-7108
- Brookview Hills Research Associates, LLC
-
-
Ohio
-
Dayton, Ohio, Estados Unidos, 45439
- Providence Health Partners-Center for Clinical Research
-
-
South Carolina
-
Columbia, South Carolina, Estados Unidos, 29203-6476
- Columbia Nephrology Associates, PA
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37923-3624
- Knoxville Kidney Center, PLLC
-
-
Texas
-
Austin, Texas, Estados Unidos, 78503
- Gamma Clinical Research Institute
-
El Paso, Texas, Estados Unidos, 79925
- Davita Clinical Research El Paso
-
El Paso, Texas, Estados Unidos, 79935
- Kidney Consultants of El Paso, P.A.
-
Houston, Texas, Estados Unidos, 77099
- Pioneer Research Solutions, Inc.
-
Houston, Texas, Estados Unidos, 77004
- DaVita Clinical Research Houston
-
San Antonio, Texas, Estados Unidos, 78251
- DaVita Clinical Research
-
San Antonio, Texas, Estados Unidos, 78212-4738
- Clinical Advancement Center, PLLC
-
San Antonio, Texas, Estados Unidos, 78229-3342
- Urology San Antonio - North Central
-
The Woodlands, Texas, Estados Unidos, 77384
- Kidney Specialists of North Houston, PLLC
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 23502
- Davita Norfolk Square
-
Richmond, Virginia, Estados Unidos, 23219
- Dominion Medical Associates, Inc.
-
-
Wisconsin
-
Kenosha, Wisconsin, Estados Unidos, 53142
- Clinical Investigation Specialists
-
Wauwatosa, Wisconsin, Estados Unidos, 53226
- Milwaukee Nephrologists, SC (Rich)
-
-
-
-
-
Batumi, Geórgia, 6010
- JSC "Evex Hospitals'
-
Tbilisi, Geórgia, 0102
- Aleksandre Aladashvili Clinic LLC
-
Tbilisi, Geórgia, 0144
- National Center of Urology Named after Laur Managadze
-
Tbilisi, Geórgia, 0112
- LTD Israel-Georgian Medical Research Clinic Helsicore
-
Tbilisi, Geórgia, 0114
- "Pineo Medical Ecosystem"LTD
-
Tbilisi, Geórgia, 0119
- JSC German Clinic
-
Tbilisi, Geórgia, 0159
- Bokhua Memorial Cardiovascular Centre
-
Tbilisi, Geórgia, 0159
- Emergency Cardiology Center named by acad. G. Chapidze
-
Tbilisi, Geórgia, 0159
- J.S.C."K.Eristavi National Center of Experimental and Clinical Surgery"
-
-
Adjara
-
Batumi, Adjara, Geórgia, 6000
- LTD "High technology hospital MEDCENTER"
-
-
Kvemo Kartli
-
Marneuli, Kvemo Kartli, Geórgia, 3000
- Ltd Marnecor
-
-
Shida Kartli
-
Gori, Shida Kartli, Geórgia, 1400
- Ministry of Defence of Georgia LEPL Giorgi Abramishvili Military Hospital
-
-
-
-
-
Hong Kong, Hong Kong
- Tung Wah Hospital
-
Hong Kong, Hong Kong
- Queen Mary Hospital - Medicine
-
-
-
-
-
Budapest, Hungria, 1083
- Semmelweis Egyetem
-
Budapest, Hungria, 1204
- Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet
-
Kaposvár, Hungria, H-7400
- Somogy Megyei Kaposi Mór Oktató Kórház
-
-
Baranya
-
Pécs, Baranya, Hungria, 7624
- Coromed-Smo Kft.
-
-
Borsod-Abauj Zemplen county
-
Miskolc, Borsod-Abauj Zemplen county, Hungria, 3530
- IPR Hungary Kft.
-
-
Csongrád megye
-
Szeged, Csongrád megye, Hungria, 6725
- Sonocor Egészségügyi Szolgáltató Kft.
-
-
Győr-Moson-Sopron
-
Mosonmagyaróvár, Győr-Moson-Sopron, Hungria, 7624
- TaNa Med Kft
-
-
Heves County
-
Hatvan, Heves County, Hungria, H-3000
- BKS Research
-
-
Pest County
-
Kistarcsa, Pest County, Hungria, 2143
- Kistarcsai Flor Ferenc Korhaz
-
-
Veszprém City
-
Balatonfüred, Veszprém City, Hungria, 8230
- DRC Gyógyszervizsgáló Központ Kft.
-
-
-
-
Central District
-
Petah Tikwa, Central District, Israel, 49100
- Rabin Medical Center
-
-
Northern District
-
Nazareth, Northern District, Israel, 16100
- Nazareth Hospital EMMS
-
-
-
-
-
Riga, Letônia
- P.Stradina Clinical University Hospital
-
-
Ogre
-
Ogre, Ogre, Letônia
- Dace Teterovska - Doctor's Practice
-
-
-
-
Kaunas County
-
Kaunas, Kaunas County, Lituânia, LT-49449
- Saules seimos medicinos centras
-
-
-
-
Kelantan
-
Kota Bharu, Kelantan, Malásia, 15586
- Hospital Raja Perempuan Zainab II
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malásia, 50586
- Hospital Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malásia, 59100
- University Malaya Medical Centre
-
-
Perak
-
Ipoh, Perak, Malásia, 30450
- Hospital Raja Permaisuri Bainun
-
Seri Manjung, Perak, Malásia, 32400
- Hospital Seri Manjung
-
-
-
-
-
Katowice, Polônia, 40-040
- Synexus Polska Sp. z o.o.
-
Lodz, Polônia, 90127
- Synexus Polska Sp. z. o.o.
-
Lodz, Polônia, 92-213
- SP ZOZ Centralny Szpital Kliniczny UM w Lodzi
-
Lublin, Polônia, 20954
- Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie
-
Poznan, Polônia, 60-702
- Synexus Polska Sp. z o.o.
-
Warsaw, Polônia, 02-672
- Synexus Polska Sp. z o.o.
-
Wroclaw, Polônia, 51-685
- WroMedica I. Bielicka, A. Strzalkowska s.c.
-
-
Kuyavian-Pomeranian Voivodeship
-
Grudziądz, Kuyavian-Pomeranian Voivodeship, Polônia, 86-300
- NZOZ Euromedica Sp. z o.o.
-
-
Lódzkie
-
Lodz, Lódzkie, Polônia, 94-074
- Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer
-
-
-
-
-
Belgrade, Sérvia, 11000
- Military Medical Academy
-
Belgrade, Sérvia, 11000
- Zvezdara University Medical Center
-
Belgrade, Sérvia
- MSB General hospital - Clinical Research Center
-
Kragujevac, Sérvia, 33126-3422
- Clinical Center Kragujevac
-
-
Belgrade
-
Zemun, Belgrade, Sérvia, 11080
- Clinical Hospital Centre Zemun
-
-
Nišavski Okrug
-
Niš, Nišavski Okrug, Sérvia, 18000
- Clinical Centre Nis
-
-
Vojvodina
-
Novi Sad, Vojvodina, Sérvia, 21000
- Clinical Center Vojvodina
-
-
-
-
-
Taichung, Taiwan, 406
- China Medical University Hospital - Nephrology - Taichung
-
Taipei, Taiwan, 110
- Taipei Medical University - Shuang Ho Hospital - Nephrology
-
Taoyuan, Taiwan, 33305
- Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Nephrology
-
-
Taichung Municipality
-
Taichung, Taichung Municipality, Taiwan, 40705
- Taichung Veterans General Hospital - Nephrology
-
-
Taipei Special Muncipality
-
Taipei, Taipei Special Muncipality, Taiwan, 10002
- National Taiwan University Hospital - Nephrology
-
-
-
-
-
Prague, Tcheca, 140 21
- IKEM
-
Prague, Tcheca, 160 00
- Alaron s.r.o.
-
-
Praha 4
-
Prague, Praha 4, Tcheca, 149 00
- Nefrologie s.r.o.
-
-
Třebíč
-
Třebíč, Třebíč, Tcheca, 674 01
- Nemocnice Trebic, p.o.
-
-
-
-
Free State
-
Bloemfontein, Free State, África do Sul, 9301
- Iatros International
-
-
Gauteng
-
Soweto, Gauteng, África do Sul, 2193
- Charlotte Maxeke Johannesburg Hospital
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, África do Sul, 4001
- Office of Gulam Hoosain Vally
-
-
Western Cape
-
Cape Town, Western Cape, África do Sul, 7530
- Tiervlei Trial Centre
-
Somerset West, Western Cape, África do Sul, 7130
- Dr J.M. Engelbrecht Trial Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Body mass index (BMI) must be ≥19 to <45 kg/m^2 at the Screening Visit
-
Participant must have uncontrolled hypertension defined as meeting both of the following criteria:
- The participant has a resting seated trough cuff SBP ≥140 mm Hg at the Screening Visit (Visit 1), and at the start (Visit 2) and end (Visit 3) of the Run-In Period
- The participant is taking 2 or more antihypertensive medications that have been titrated upward as tolerated to hypertension target doses per local SoC and have been stable (i.e., without any dose adjustments) from 4 weeks before the Screening Visit (Visit 1) through the end of the Run-In Period (Visit 3)
-
The participant must have Stage 3b (eGFR [EPI] ≥30 and ≤44 mL/min/1.73 m^2) or Stage 4 (eGFR [EPI] ≥15 and <30 mL/min/1.73 m^2) CKD.
Exclusion Criteria:
- Participant has a resting seated trough cuff SBP ≥180 mm Hg at the Screening Visit (Visit 1) or at the start (Visit 2) or end (Visit 3) of the Run-In Period
- Participant has a serum potassium level >4.8 mmol/L during the Screening or Run-In Periods
- Participant has had a serum potassium level >5.6 mmol/L within 2 weeks before the Screening Visit (Visit 1)
- Participant has been hospitalized for hyperkalemia within the 3 months before the Randomization Visit (Visit 3)
- Participant was not compliant with taking placebo during the Run-in Period or participant was not compliant with background antihypertensive medications during the Run-in Period as assessed at the Randomization Visit (Visit 3)
- Participant has taken an mineralocorticoid receptor antagonist (MRA), a potassium-sparing diuretic, or chronic potassium supplements during the 4 weeks before the Screening Visit (Visit 1)
- Participant has taken potassium binders for the treatment of hyperkalemia during the 3 months before the Screening Visit (Visit 1)
- Participant has taken a strong cytochrome P450 (CYP) CYP3A4 inducer or strong CYP3A4 inhibitor during the 7 days before the Randomization Visit (Visit 3)
- Participant has taken a prohibited traditional Chinese medication during the 28 days prior to Screening Visit (Visit 1).
- Participant was administered any other investigational product within 4 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit (Visit 1).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
Open-label Placebo Run-In Period: All eligible participants will receive matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive matching placebo, from week 2 thru week 24 during the Double-blind treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56. |
Participants will orally receive placebo matching to KBP-5074 tablets QD. |
|
Experimental: KBP-5074
Open-label Placebo Run-In period: All eligible participants will receive matching placebo, for approximately 2 weeks during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive KBP-5074, from week 2 thru week 24 during the Double-blind Treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56. |
Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Seated Trough Cuff Systolic Blood Pressure (SBP) From Baseline to Week 12
Prazo: From baseline to Week 12
|
Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, was evaluated. |
From baseline to Week 12
|
|
Change in Seated Trough Cuff SBP From Week 48 to Week 52
Prazo: From Week 48 to Week 52
|
Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, was evaluated. |
From Week 48 to Week 52
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Seated Trough Cuff SBP From Baseline to Week 24
Prazo: From baseline to Week 24
|
Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, were evaluated. |
From baseline to Week 24
|
|
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 12
Prazo: From baseline to Week 12
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated. |
From baseline to Week 12
|
|
Changes in Urinary Albumin: Creatinine Ratio (UACR) From Baseline to Week 12 for Participants With UACR ≥30 mg/g at Baseline
Prazo: From baseline to Week 12
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated. |
From baseline to Week 12
|
|
Percentage Changes in UACR From Baseline to Week 12 and Week 24 for Participants With UACR ≥30 mg/g at Baseline
Prazo: From baseline to Week 12 and Week 24
|
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From baseline to Week 12 and Week 24
|
|
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 24
Prazo: From baseline to Week 24
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated. |
From baseline to Week 24
|
|
Changes in Seated Trough Cuff DBP From Baseline to Week 48
Prazo: From baseline to Week 48
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff SBP was evaluated. |
From baseline to Week 48
|
|
Changes in Seated Trough Cuff SBP From Baseline to Week 48
Prazo: From baseline to Week 48
|
Effect of KBP-5074 on SBP by assessing change in seated trough cuff SBP was evaluated. |
From baseline to Week 48
|
|
Changes in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at Baseline
Prazo: From baseline to Week 24
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline was evaluated. |
From baseline to Week 24
|
|
Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria
Prazo: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria
Prazo: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Change in Seated Trough Cuff DBP From Week 48 to Week 52
Prazo: From Week 48 to Week 52
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated. |
From Week 48 to Week 52
|
|
Change in UACR From Week 48 to Week 52 for Participants With UACR ≥30 mg/g at Baseline
Prazo: Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
Week 48 to Week 52
|
|
Percentage Change in UACR From Week 48 to Week 52 in Participants With UACR ≥30 mg/g at Baseline
Prazo: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Prazo: Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)
|
The safety and tolerability of KBP-5074 was evaluated. A treatment emergent adverse event (TEAE) was defined as any AE with onset during or after first dose and before 4 weeks after last dose of study drug, or any preexisting AE/condition that worsened during this period. Selected TEAEs include Hyperkalemia, Hypertension, Hypotension, and eGFR Decrease. |
Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)
|
|
Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria
Prazo: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline, was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria
Prazo: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria
Prazo: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Percentage Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria
Prazo: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria
Prazo: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Percentage Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria
Prazo: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Vasculares
- Doenças cardiovasculares
- Processos Patológicos
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doença crônica
- Atributos da doença
- Insuficiência renal
- Condições Patológicas, Sinais e Sintomas
- Hipertensão
- Insuficiência Renal Crônica
- KBP-5074
Outros números de identificação do estudo
- KBP5074-3-001
- 2021-003636-88 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .